Benefits
Eye health and visual function
Two supplier-sponsored placebo-controlled trials tested astaxanthin alone on screen-related eye fatigue: children had lower eye-strain questionnaire scores, and adults aged 40 and over kept better visual acuity after screen work (details below). In mice, astaxanthin protected the retina from light damage. No trial shows it prevents or treats eye disease.
Skin moisture and elasticity
In a pooled analysis of eight small randomized trials of oral astaxanthin (2 to 12 mg/day for 4 to 16 weeks, mostly middle-aged adults with signs of skin aging; two trials paired low-dose astaxanthin with collagen or tocotrienol), skin moisture and elasticity improved versus control but wrinkle depth did not, and results varied between trials. No pill replaces sunscreen.
Cardiovascular and lipid support
A pooled analysis of 7 trials in 321 adults at risk of metabolic syndrome found a significant drop in LDL cholesterol and only marginal changes in total cholesterol and systolic blood pressure. In a separate 8-week trial in 50 adults with coronary artery disease, 12 mg/day lowered cholesterol within the group but not significantly more than placebo.
Cognitive function in middle-aged and older adults
In 96 healthy middle-aged and older adults with age-related forgetfulness, 12 mg/day for 12 weeks improved scores on a computerized test battery within the group, and maze-learning scores improved earlier than with placebo. Overall there was no significant difference from placebo, which the authors attribute to the small sample.
Oxidative stress markers in human trials
In young healthy women, 2 or 8 mg/day for 8 weeks lowered a DNA damage marker but did not change lipid peroxidation. In women undergoing fertility treatment, 8 mg/day for 40 days raised blood antioxidant capacity and catalase versus placebo, while other oxidative markers did not change and pregnancy rates were not improved.
Digital eye strain and visual fatigue after screen use
Two placebo-controlled trials tested Haematococcus astaxanthin alone. In 64 children aged 10 to 14 with screen-related eye strain, 4 mg/day for 84 days lowered eye-strain and visual-fatigue questionnaire scores more than placebo; acuity and tear tests did not differ. In 60 adults, 9 mg/day for 6 weeks better preserved visual acuity after screen work only in those aged 40 and over. Both were run or sponsored by astaxanthin suppliers.
Mechanism of action
Antioxidant Activity
Astaxanthin neutralizes reactive oxygen species and free radicals. In laboratory model membranes, astaxanthin (a polar carotenoid) preserved membrane structure and lowered lipid peroxidation by about 40%, whereas beta-carotene and lycopene disordered the membrane and increased it. In one human trial it raised blood catalase and total antioxidant capacity but not superoxide dismutase.
Inflammation Signaling
Lab and animal studies suggest astaxanthin can dampen inflammatory signaling. Human results are mixed: in an 8-week trial in young women, C-reactive protein was lower at 2 mg/day while IL-6 rose at 8 mg/day, and in adults with coronary artery disease TNF-alpha did not change.
Protection Against UV and Photo-Oxidative Damage
In cultured skin cells, astaxanthin suppressed UVB-induced inflammatory cytokine release. In a 10-week placebo-controlled trial in 23 healthy adults, 4 mg/day raised the UV dose needed to redden the skin (minimal erythema dose) compared with placebo. In mice it protected the retina from light-induced damage; it has not been shown to prevent eye disease in people.
Cardiovascular Support
Astaxanthin may limit oxidative damage to low-density lipoprotein (LDL): in a small study of young volunteers, 14 days of supplementation lengthened the time their LDL took to oxidize in laboratory tests. In hypertensive rats and isolated arteries it promoted nitric oxide related vessel relaxation; pooled human trials show at most a marginal effect on blood pressure.
Neuroprotection
In rats, dietary astaxanthin reaches the brain (hippocampus and cerebral cortex), and in mice with reduced blood flow to the brain it was neuroprotective and improved maze learning. Whether this translates to people is unknown.
Immune Modulation
In one small 8-week trial in young healthy women, astaxanthin increased natural killer (NK) cell cytotoxic activity, lymphocyte proliferation and total T and B cell counts.
Clinical trials
Randomized, double-blind, placebo-controlled clinical study in 65 healthy women; 6 mg or 12 mg/day astaxanthin or placebo for 16 weeks, with in vitro work on UV-induced damage (Tominaga et al. 2017, J Clin Biochem Nutr)
65 healthy Japanese women. 16-week intervention from August to December.
Over 16 weeks (August to December), wrinkle depth and skin moisture significantly worsened with placebo but did not change significantly with astaxanthin, suggesting it prevented seasonal skin deterioration rather than improving skin beyond baseline. Stratum-corneum interleukin-1 alpha rose in the placebo and low-dose groups but not the high-dose group. The study was funded by an astaxanthin manufacturer and its authors are from AstaReal Co., Ltd.
Randomized, double-blind, placebo-controlled trial of astaxanthin-rich Haematococcus pluvialis extract (6 mg or 12 mg/day astaxanthin) vs placebo for 12 weeks in 96 healthy middle-aged and older adults with age-related forgetfulness. Outcomes: CogHealth and Groton Maze Learning Test scores (Katagiri et al. 2012, J Clin Biochem Nutr)
96 healthy middle-aged and older adults with age-related forgetfulness. 12-week intervention.
CogHealth battery scores improved within the 12 mg group after 12 weeks, and Groton Maze Learning scores improved earlier in the 6 mg and 12 mg groups than in placebo. The authors state the sample was too small to show a significant difference between astaxanthin and placebo, so this is a positive but underpowered result. No adverse effects were seen.
Randomized, double-blind, placebo-controlled trial (NCT03991286) in infertile women with polycystic ovary syndrome undergoing assisted reproduction; astaxanthin 8 mg/day or placebo for 40 days. Outcomes: serum and follicular-fluid oxidative stress markers, the Nrf2 antioxidant pathway in granulosa cells, oocyte quality and pregnancy outcomes (Gharaei et al. 2022, J Assist Reprod Genet)
40 infertile women with PCOS undergoing ART (20 per group completed and were analyzed). 40-day intervention.
Astaxanthin raised serum total antioxidant capacity and catalase and activated the Nrf2 antioxidant pathway in granulosa cells versus placebo, and the share of mature (MII) oocytes and good-quality embryos rose. However, chemical and clinical pregnancy rates did not differ from placebo and follicular-fluid oxidative markers were unchanged. These are surrogate and intermediate measures, not a live-birth benefit, in a small trial that needs replication.
Randomized, double-blind, placebo-controlled trial (IRCT20201227049857N1) in 50 adults with coronary artery disease; astaxanthin 12 mg/day or placebo for 8 weeks. Outcomes: lipid panel, glycemic indices, TNF-alpha, Sirtuin1, BMI and body composition (Heidari et al. 2023, Front Nutr)
50 CAD patients. 8-week intervention.
Total and LDL cholesterol fell significantly within the astaxanthin group (by about 15 mg/dL each), but the authors report the differences versus placebo were not statistically significant; most patients were already taking statins. Triglycerides and HDL cholesterol were not affected, and body composition, glycemic indices (including HOMA-IR), TNF-alpha and Sirtuin1 did not differ from placebo. 44 of the 50 patients completed the trial.
Multicenter, randomized, double-blinded, placebo-controlled 12-week trial of a commercial complex providing 2 mg astaxanthin, 321 mg krill oil and 30 mg hyaluronic acid daily in 100 Korean adults with mild knee or hip osteoarthritis. Primary outcome: joint pain on a visual analog scale; secondary: K-WOMAC pain, stiffness and function (Hill et al. 2023, Nutrients)
100 adults with mild knee or hip osteoarthritis (75 in the per-protocol analysis). 12-week intervention.
At 12 weeks the complex reduced joint pain on the visual analog scale (the primary outcome) more than placebo. K-WOMAC total and function scores improved more than placebo only in unadjusted analyses, and per the authors' 2024 correction, K-WOMAC pain and stiffness did not differ. Astaxanthin's own contribution cannot be isolated from this three-ingredient formula. The study was industry-funded and co-authored by staff of the product's supplier and maker.